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ABSTRACT
To obtain truly informed consent, we must be able to advise our patients accurately about the relative risk and benefit of
any treatment plan. Percutaneous renal biopsy remains the gold standard investigation in the evaluation of intrinsic renal
disease. There have been significant improvements in practice over the past decades with regards to percutaneous renal
biopsy. Across centres, we appear now to have reached agreement on many aspects of this procedure, such as the need for
blood pressure control, avoidance of coagulopathy, use of spring-loaded needles under direct imaging guidance and a need
to monitor for complications. The authors from Rush University Medical Centre provide reassurance that renal biopsy in
the modern era remains a safe procedure with a low rate of significant bleeding. There remain areas of divergence in
practice that may have unintended and deleterious consequences: administration of desmopressin and discontinuation of
aspirin, for example, both carry a risk of thrombosis. It is our opinion that it is time to reach consensus on our
interpretation of the available data and to draw up guidelines to standardize our biopsy practice internationally.
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INTRODUCTION
To obtain truly informed consent, we must be able to advise our
patients accurately about the relative risk and benefit of any treat-
ment plan. Percutaneous renal biopsy remains the gold standard
investigation in the evaluation of intrinsic renal disease. The use of
spring-loaded biopsy needles under direct radiological (commonly
ultrasound) guidance is now standard practice. These needles
boast a more favourable risk profile compared with the older Tru-
Cut or Vim-Silvermann devices; significant complications that
threaten the life of the patient or the kidney are rare. Here, we de-
scribe the findings of two studies from Rush University Medical
Centre and discuss the current evidence and its limitations regard-
ing the interpretation of bleeding risk in advance of renal biopsy.
Bleeding complications after renal biopsy
In this issue of CKJ, the group from Chicago present findings
from their biopsy practice spanning two decades. Whittier et al.
[1] look at the risk of complications in native versus transplant
renal biopsies from 1995 to 2015, whilst Korbet et al. [2] compare
the risk of complications in patients undergoing native renal bi-
opsy for acute kidney injury (AKI) versus other indications from
1991 to 2015. All biopsies were conducted with modern spring-
loaded biopsy needles: 88% of native biopsies were conducted
using 14-gauge needles; the remaining native and all transplant
biopsies used 16-gauge needles. Patients undergoing biopsy
were generally expected to have controlled blood pressure and
normal clotting parameters, including prothrombin time, acti-
vated partial thromboplastin time and bleeding time. In
patients with abnormal bleeding time, desmopressin was ad-
ministered in some cases at the discretion of the responsible
physician. A major bleeding complication was defined as bleed-
ing requiring intervention: surgery, interventional radiology
procedure, readmission, blood transfusion or death.
Whittier et al. [1] report excellent diagnostic yield: 92% of 767
native and 88% of 938 renal transplant biopsies contained at
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least 10 glomeruli, with adequate tissue for diagnosis in over
99% of cases. The rate of major complications or blood transfu-
sion alone were 5.9 and 5.2%, respectively, in native renal biop-
sies, and 3.8 and 3.3%, respectively, in renal transplant biopsies.
These complication rates are higher than in other published se-
ries [3–7], and blood transfusion accounts for the majority. This
may reflect differences in biopsy or transfusion practices in this
centre compared with other units. For example, authors from
this centre have reported previously that around half of all
blood transfusions were administered for haematoma (regard-
less of starting haemoglobin level), and routinely undertake ul-
trasound screening at 1 h post-biopsy [8]. Second, the routine
use of 14-gauge biopsy needles for native renal biopsy may be
associated with a higher rate of bleeding complications [9–11].
Third, smaller centre size (performing fewer than 30 biopsies
per year or 1 per week) has been associated with greater compli-
cation rate [5]. Whittier et al. describe data from a centre in
which an average of 37 native and 47 transplant biopsies were
conducted per year. For comparison, the rate of major complica-
tion in our centre is 2.2% (1.8% transfusion): we conduct >170
native kidney and 80 transplant biopsies per year, of which
>90% are performed by nephrology trainees [3]. Finally, the
authors routinely observe patients after native biopsy for 24 h
and transplant biopsy for 8 h. Whittier et al. acknowledge that
asymptomatic patients observed overnight may undergo fur-
ther investigation for a bleeding complication based on labora-
tory results. The clinical significance of this is unclear.
Korbet et al. [2] report data on the rate of major complica-
tion following native renal biopsy for AKI versus other indica-
tion. Of 955 native renal biopsies reviewed, 160 (16.8%) were
undertaken for AKI. Patients biopsied for AKI were older (58
versus 44 years) and had higher serum creatinine (4.5 versus
1.8 mg/dL), lower haemoglobin (10.4 versus 12.2 g/dL) and a
greater proportion had clotting abnormalities. There was a
higher rate of major complication seen in the AKI group, com-
pared with the group biopsied for other indications [11.3 versus
6.7%; odds ratio 1.78, 95% confidence interval (CI) 1.01–3.12].
Perinephric haematoma was common, occurring in 72.2% of
the AKI group and 79.2% of non-AKI patients, which again may
reflect routine ultrasound screening at 1 h. There was a high
proportion of blood transfusion in patients biopsied for AKI
(10.0% versus 5.1%, P¼ 0.02). Lower haemoglobin, female gen-
der, increased systolic blood pressure and higher serum creati-
nine were risk factors for major complication in this group on
multivariate analysis.
Patients were routinely observed for complication for a 24-
h period after native biopsy and 8 h after transplant biopsy in
this centre; the proportion of complications occurring beyond
an 8-h window after biopsy were similar for both native (28%)
and transplant (26%) biopsies. Reassuringly, the absolute num-
ber of complications requiring readmission was small: fewer
than 7 readmissions per year for native renal biopsies; 10 read-
missions per year for transplant. The authors point out that an
extended period of observation likely increases the detection of
complications, and therefore the proportion of complications
detected beyond 8 h, which might otherwise be missed. This is
corroborated by other reports with up to a third [12, 13] and up
to 12.5% [14, 15] of complications detected beyond 8 h in
patients undergoing native and transplant biopsy, respectively.
Serious complications can present late and without early fea-
tures of concern. Redfield et al. [15] reported time to any compli-
cation of 5.6 h (SD 13.8), but time to severe or life-threatening
complication of 12.4 h (SD 12.1)—54% of these developing
beyond 8 h—though with significant variability from the mean.
We do not know the clinical impact of a complication occurring
out of hospital versus in hospital, and whether the former has
deleterious effects on patient outcome. Indeed, day-case proce-
dures are commonly undertaken in some centres (including our
own) without increased risk of complications [3, 16–18]. We
must be pragmatic and balance the relative risk of complication
with the expense and alternative risks of an extended hospital
stay.
Unintended consequences
The authors report that they occasionally administer desmo-
pressin (DDAVP) to correct bleeding time [1] and it is their rou-
tine practice to withhold aspirin prior to renal biopsy [8]. While
both practices are common there is no clear consensus on the
correct approach to these issues. Both administering desmo-
pressin and withholding aspirin may have unintended, harmful
consequences for the patient.
Desmopressin and bleeding time
Desmopressin, a vasopressin analogue, is licensed for use in
patients with haemophilia A and von Willebrand’s disease to
reduce clinically significant bleeding. It works by increasing cir-
culating levels of factor VIII and von Willebrand factor. The data
available on the use of desmopressin for the treatment of bleed-
ing in other disorders of platelet function with more complex
pathophysiology (such as uraemia, recent use of antiplatelets or
isolated prolongation of bleeding time) are less convincing.
Desmopressin appears to reduce bleeding time in healthy
aspirin-treated volunteers and in those individuals with an iso-
lated prolonged bleeding time [19]. A meta-analysis of 10 trials
(596 patients) of desmopressin in patients with platelet dys-
function (antiplatelet use or cardiopulmonary bypass) reported
reduction in transfusion rates, blood loss and re-operation rates
compared with placebo [20]. However, half of the included stud-
ies were conducted >20 years ago and all were in patients un-
dergoing cardiac surgery, which carries specific risk factors for
platelet dysfunction [20]. An older meta-analysis of 16 studies
(1215 patients) in cardiac surgery suggested that the use of des-
mopressin versus placebo more than doubles the risk of periop-
erative myocardial infarction, without any significant benefit
on transfusion rate, further operations relating to bleeding or
mortality [21]. Desmopressin is relatively contraindicated in
patients with cardiovascular disease, prevalent amongst
patients with kidney disease, because of the reported risk of
acute thrombosis (resulting in ischaemic stroke and myocardial
infarction) [22].
There are limited and contradictory data regarding the use
of desmopressin for renal biopsy specifically. In a single-centre,
randomized, double-blind, placebo-controlled trial in 162
patients, desmopressin significantly reduced haematoma size,
but there was no change in haemoglobin level in either group.
Similarly, no patient in this study experienced visible haematu-
ria, or required blood transfusion, radiological or surgical inter-
vention [23]. All included patients in this study were considered
low risk, in that they had preserved renal function (glomerular
filtration rate >60 mL/min and creatinine <150 mmol/L), con-
trolled blood pressure and normal coagulation parameters. In a
retrospective analysis of a multi-centre registry of native renal
biopsies in patients with creatinine >150 mmol/L, those who re-
ceived desmopressin had substantially fewer major and minor
complications than those who did not [24]. However, relatively
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few biopsies were conducted across these centres (20/year in
the centre that administered desmopressin; 37/year total across
the remaining six centres). Variation in practice and operator
skill mix may also account for higher rates of complications in
centres that did not administer desmopressin [5].
Despite the lack of convincing evidence of benefit, and po-
tential risk of harm, desmopressin is still used in some centres
at the discretion of the responsible physician, and often in reac-
tion to prolonged bleeding time: the time taken for bleeding to
stop after infliction of a small skin wound. Measurement of
bleeding time may be influenced by numerous factors that are
difficult to standardize, including technical variables, use of
concomitant medications and comorbidities [25]. The result is
that neither normal nor abnormal bleeding times have been
found to be reliable in predicting major bleeding associated
with invasive procedures [25]. Similarly, bleeding time is not a
reliable method of identifying patients with platelet dysfunction
in association with recent aspirin/antiplatelet use [25]. As such,
bleeding time is not recommended for routine assessment of
bleeding risk in advance of major procedures including surgery
[25–27]. By extension, there is no evidence for routine correction
of abnormal bleeding time with desmopressin.
Aspirin
A systematic review of bleeding complications in patients un-
dergoing renal biopsy on aspirin reports on four clinical guide-
lines and two non-randomized studies [4, 28–32]. Kumar et al.
conclude that it is reasonable to withhold aspirin for 7–10 days
in advance of renal biopsy because of lack of prospective evi-
dence that biopsy on aspirin is safe [32]. There are a few prob-
lems with this proposition. First, stipulating that aspirin must
be discontinued necessarily delays biopsy and definitive treat-
ment. Second, and most importantly, there are no prospective
controlled trials describing the broader outcomes after renal bi-
opsy in those advised to stop aspirin, particularly relating to
thrombotic complications and cardiovascular events.
Cardiovascular disease affects two-thirds of older persons
with CKD [33, 34]—the majority with atherosclerotic heart
disease—and accounts for 39% of deaths in patients on dialysis
[34] and at least 22% of deaths in those with a kidney transplant
[33]. Around 30% of adults aged over 40 years in the US report
taking low-dose aspirin for primary or secondary prevention of
cardiovascular disease [35]. In a major study of over 600 000
patients using low-dose aspirin for primary or secondary car-
diovascular disease prevention, discontinuation of aspirin was
associated with immediate and substantial (37%) increased risk
of cardiovascular events, equivalent to one additional cardio-
vascular event per year for every 74 patients who stop aspirin
[36]. The risk of aspirin cessation is further supported by a
meta-analysis of aspirin discontinuation or non-adherence in
patients at risk for coronary heart disease. Biondi-Zoccai et al.
[37] describe 3-fold increase in major adverse thrombotic events
(including acute myocardial infarction, stroke, other thrombo-
sis, death) in patients who have discontinued aspirin, with aver-
age time to event of 10.7 days (95% CI 10.3–11.1). An earlier
meta-analysis by Burger et al. [38] suggests this time interval
could be even shorter for acute coronary syndrome alone
(8.56 3.6 days).
International consensus guidelines support ongoing use of
aspirin for transbronchial lung biopsy [39]. In a prospective
study to determine risk of bleeding with aspirin use in 1217
patients undergoing transbronchial lung biopsy, there was a
similar rate of procedure-related bleeding compared with renal
biopsy [40], but no increased risk of mild, moderate or severe
bleeding in those 285 patients (23.4%) who took low-dose aspirin
within 24 h of the procedure [40]. Similarly, Atwell et al. [31] de-
scribe data on 15 181 percutaneous core biopsies of any organ
taken between 2002 and 2006, with a similar rate of bleeding in
patients taking aspirin (within 10 days of biopsy) compared with
those who did not (0.6 versus 0.4%, P¼ 0.34). Amongst 5832
patients in this cohort undergoing renal biopsy, there was no
association between aspirin use and risk of bleeding (P¼ 0.53).
In our own unit, we previously compared the rate of bleeding
complications in our two centres before they merged in 2007 [4].
Routine practice in one centre was to stop aspirin 5 days before
renal biopsy; aspirin was routinely continued in the other.
There was no difference in the rate of major bleeding (need
for transfusion or surgical/radiological intervention), and our
standard practice has been to continue low-dose aspirin for re-
nal biopsy, without increase in our rate of bleeding complica-
tions [3].
CONCLUSIONS
There have been significant improvements in practice over the
past decades with regards percutaneous renal biopsy. Across
centres, we appear now to have reached agreement on many
aspects of this procedure, such as the need for blood pressure
control, avoidance of coagulopathy, use of spring-loaded nee-
dles under direct imaging guidance and a need to monitor for
complications. Whittier et al. and Korbet et al. provide reassur-
ance that renal biopsy in the modern era remains a safe proce-
dure with low rate of significant bleeding, albeit reporting
findings from a single centre. The observed complication rate
differs between centres according to variation in practice and in
the definition of major complications, but the event rate of ma-
jor complication is so low that either a single centre case series
over a prolonged period (as in these articles) or a registry col-
lecting data from a large area are required. We have chosen the
latter, and have developed a national Renal Biopsy Registry and
publish the outcomes as part of our annual renal registry report
[41]. There remain areas of divergence in practice that may have
unintended and deleterious consequences: administration of
desmopressin and discontinuation of aspirin, for example, both
carry a risk of thrombosis. It is our opinion that it is time to
reach consensus on our interpretation of the available data
and to draw up guidelines to standardize our biopsy practice
internationally.
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